NCT04787185

Stereotactic Radiotherapy in Association With Immunotherapy for the Treatment of NSCLC Brain Metastases

STRAIT-LUC Trial: Stereotactic Radiotherapy (SRT) in Association With Immunotherapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer (NSCLC): a Multicenter Prospective Observational Study

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Azienda Ospedaliero-Universitaria Careggi · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study's primary objective is the evaluation of toxicities reported during RS or HFSRT in patients with brain metastases from NSCLC undergoing immunotherapy (Safety), with particular reference to the rate of symptomatic radionecrosis and intralesional hemorrhage. Others primary objectives of the study are the Feasibility and the intracranial control of the disease, both local (site radiotherapy treatment) and at a distance (intracranial, but at a distance from the site of the disease treated with stereotaxic radiotherapy). The secondary objectives concern quality assessment of life of the patients under study (Quality Of Life, QoL).

Conditions

• Brain Metastases From NSCLC

Interventions

Type	Name	Description
RADIATION	Valutation of toxicity	Observation of toxicity All patient with Brain metastases from NSCLC who are candidates for RS or HFSRT in course of immunotherapy

Timeline

• Start date: 2020-04-17
• Primary completion: 2021-12-01
• Completion: 2021-12-01
• First posted: 2021-03-08
• Last updated: 2021-03-08

Locations

1 site across 1 country: Italy